Tue. 20 Feb 2024, 7:03pm ET
Benzinga
Earnings, News
Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(1.15) by 36.52 percent. This is a 48.23 percent increase over losses of $(1.41) per share from the same period last year. The company reported quarterly sales of $71.53 million which beat the analyst consensus estimate of $67.69 million by 5.67 percent. This is a 193.50 percent increase over sales of $24.37 million the same period last year.